美亚光电 20230331 公司新发布的口腔显微镜产品，其产品力、与市场主要品牌（如速迈）的对标 情况、售价以及 2026 年的收入贡献预期是怎样的？ 口腔显微镜作为口腔医疗的必备影像设备之一，补全了公司的口腔影像设备产 品线，未来具有不错的发展空间。该产品刚推出，具体的售价和市场预期尚难 判断。目前公司的业务重心仍以口腔 CBCT 为主，口腔显微镜是有效的补充， 旨在为终端客户提供口腔数字化的整体解决方案。关于产品的具体售价信息， 可以通过官方网站或经销商渠道了解。 公司在年报中提及了 AI 赋能以及美亚美牙云平台（智云）的进展，2025 年智 云收入接近 100 万元，请问 2026 年智云的发展潜力和盈利预期如何？ 2025 年医疗板块收入下滑近 10%但降幅收窄，通过主动收缩低毛利产 品销售，实现医疗设备毛利率企稳及利润端优异表现。 色选机业务营收占比超 70%，其中再生资源分选业务 2025 年营收超 3 亿元且维持双位数增长，成为核心增长引擎。 CBCT 出口业务进入爆发期，2025 年出口量翻倍至 200 余台，虽目前 收入占比不足 10%，但海外毛利率比国内高约 10 个百分点。 2025 年 ...

证券代码：002690 证券简称：美亚光电 合肥美亚光电技术股份有限公司 投资者关系活动记录表 编号：T2026-001 投资者关 系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ■电话交流会 活动参与人员 创金合信基金 张小郭、中泰证券 郑雅梦 卢安宇、中金公司 张杰敏、天风证券 杜玙、国联基金 焦阳、弘尚资产 张骏、华夏基金 吕佳玮、光大证券 刘勇、方 正证券 张陆佳、长城国瑞证券 胡晨曦、长江证券资管 汪中昊、前海开源基金 张 宇翔、华安基金 杨明、阳光资产 李曦辰、财通证券资管 易小金、稷定私募基 金 马骁翔、广发证券 汪家豪、兴业证券 祁佳仪、恒林股份 陈建富、招商证券 陈之馨、国信证券 张宇翔、华西证券 王好尚、中信证券 刘海博、国海证券 张 钰莹、华福证券 卢大炜、谷雨嘉禾基金、第一创业证券 许也可、九泰基金 赵 万隆、上海晨燕资产 倪耿皓、华富基金 虞伟、国投瑞银证券 袁野、Harding Loevner Lee Gao、上海诚熠 施瑞霖、国联民生证券 占豪、轩瑞私募基金 黄登 峰、华泰证券 杨任重、方正证券 张其超、杭州九慕资产 强紫 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% against the benchmark index within the next 6 to 12 months [17]. Core Insights - The company reported a revenue of 2,407 million yuan for 2025, reflecting a year-on-year growth of 4.16%, and a net profit attributable to shareholders of 719 million yuan, which is a 10.77% increase year-on-year [4][5]. - The company has shown significant improvement in profitability, with a gross margin of 53.92% in 2025, up by 3.49 percentage points year-on-year, and a net profit margin of 29.88%, increasing by 1.79 percentage points year-on-year [6][7]. - The company is focusing on technological innovation in the dental medical field, launching new products and applications, and is optimistic about future growth despite current market challenges [12]. Summary by Relevant Sections Financial Performance - In 2025, the company achieved a revenue of 2,407 million yuan, with a projected revenue growth rate of 14% for 2026 [3][4]. - The net profit for 2025 was 719 million yuan, with an expected growth of 18% in 2026 [3][4]. - The earnings per share (EPS) for 2025 is projected at 0.82 yuan, with an increase to 0.96 yuan in 2026 [3][4]. Profitability Analysis - The company’s gross margin improved to 53.92% in 2025, driven by enhanced production efficiency and a favorable product mix [6][7]. - The net profit margin also increased, indicating better cost management and operational efficiency [7]. Operational Efficiency - Inventory turnover days decreased to 97.28 days, and accounts receivable turnover days improved to 63.33 days, reflecting better sales channel optimization and inventory management [8]. - The company’s operating cash flow reached 9.62 billion yuan, indicating a steady improvement in operational quality [8]. Research and Development - The company invested 164 million yuan in R&D in 2025, representing 6.81% of its revenue, and holds a significant number of patents, indicating a strong commitment to innovation [8][12]. Market Position and Growth Potential - The company is a leader in the color sorting machine industry, with a revenue of 1,753 million yuan in 2025, growing by 8.05% year-on-year [9]. - The dental medical segment, while currently facing challenges, is expected to recover, with the company continuing to invest in this area [12]. Future Outlook - The company anticipates a net profit of 846 million yuan in 2026, with a growth rate of 17.64%, and further growth projected for 2027 and 2028 [13]. - The demand for color sorting machines remains robust, and the dental sector is expected to provide long-term growth opportunities [13].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the medical research outsourcing and chemical preparations sectors showed positive growth, while hospitals and blood products faced declines [2][13]. - The report notes that the innovative drug licensing transactions in China exceeded $60 billion in the first quarter of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. Important Industry News - The NMPA has launched a three-year "Spring Rain Action" to promote the transformation of clinical innovation achievements in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has received FDA approval, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has been approved by the FDA, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, becoming the first of its kind domestically [46]. Investment Suggestions - The report suggests focusing on innovative drug companies with core technology platforms and differentiated pipeline layouts, especially those expected to achieve positive catalysts at major academic conferences like AACR [5]. - It also recommends attention to the CXO/CDMO industry chain, which is expected to benefit from improved overseas R&D demand and order recovery [5].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% against the benchmark index in the next 6 to 12 months [17]. Core Insights - The company reported a revenue of 2.407 billion yuan for 2025, reflecting a year-on-year growth of 4.16%, and a net profit attributable to shareholders of 719 million yuan, up 10.77% year-on-year [4][5]. - The company has shown significant improvement in profitability, with a gross margin of 53.92%, an increase of 3.49 percentage points year-on-year, and a net profit margin of 29.88%, up 1.79 percentage points year-on-year [7]. - The company is focusing on technological innovation in the dental medical field, launching new products and applications, and is optimistic about future growth despite current market challenges [12]. Financial Performance Summary - Revenue and Profit Forecast: - 2024A: Revenue of 2.311 billion yuan, net profit of 649 million yuan - 2025A: Revenue of 2.407 billion yuan, net profit of 719 million yuan - 2026E: Revenue of 2.749 billion yuan, net profit of 846 million yuan - 2027E: Revenue of 3.112 billion yuan, net profit of 981 million yuan - 2028E: Revenue of 3.485 billion yuan, net profit of 1.127 billion yuan [3][14]. - Growth Rates: - Revenue growth rates are projected at -5% for 2024, 4% for 2025, and 14% for 2026, with net profit growth rates at -13% for 2024, 11% for 2025, and 18% for 2026 [3][14]. Operational Efficiency - The company has improved its inventory turnover days to 97.28 days, a decrease of 12.28 days year-on-year, and accounts receivable turnover days to 63.33 days, down 16.41 days year-on-year, indicating better sales channel optimization and cost control [8]. - The company’s R&D investment reached 164 million yuan in 2025, accounting for 6.81% of revenue, with a slight decrease of 0.09 percentage points year-on-year [8]. Market Position and Product Development - The color sorting machine segment continues to grow steadily, with revenue reaching 1.753 billion yuan in 2025, an increase of 8.05% year-on-year, and a gross margin of 54.26%, up 4.62 percentage points [9]. - The company is a pioneer in the domestic color sorting industry, focusing on innovation and expanding its product applications across various sectors [9]. Future Outlook - The company is optimistic about the dental medical market despite current downturns, with a projected revenue of 454 million yuan from medical equipment in 2025, although this represents a decline of 9.75% year-on-year [12]. - The introduction of the "Meiya Dental Health Digital Cloud Platform" aims to enhance operational efficiency and is expected to contribute to revenue growth as AI applications develop [13].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the innovative drug sector is currently the core focus, supported by favorable domestic policies such as the NMPA's "Spring Rain Action" to promote clinical innovation in medical devices [4][5]. - The total amount of innovative drug licensing transactions in China exceeded $60 billion in the first three months of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. - The report suggests focusing on companies with core technology platforms and differentiated pipeline layouts, particularly those expected to achieve positive catalysts at major academic conferences like AACR [5]. Important Industry News - The NMPA has initiated a three-year "Spring Rain Action" to support the transformation of clinical innovation in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has been approved by the FDA, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has received FDA approval, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, making it the first of its kind domestically [46]. Company Dynamics - Novartis plans to invest over 3.3 billion RMB in China to enhance its R&D, production, and operational capabilities [48].

证券研究报告 美亚光电 (002690 CH) 看好新品带动盈利能力持续提升 | 华泰研究 | | | 年报点评 | 投资评级(维持): | 增持 | | --- | --- | --- | --- | --- | --- | | 2026 年 | 3 月 | 31 日│中国内地 | 专用设备 | 目标价(人民币): | 22.50 | 公司发布 25 年年报，收入 24 亿，同比+4%，归母净利润 7.2 亿，同比+11%， 其中 25Q4 单季度实现收入 7.1 亿，同比-3%，归母净利润 2 亿，同比+0.6%。 公司年报利润略微高于我们此前报告中 7.0 亿的预期，超出原因主要系下半 年毛利率有所提升。25 年公司色选机业务维持稳健增长，同时 CBCT 行业 竞争有所缓和，看好后续稳健的盈利表现和高分红属性，维持"增持"评级。 聚焦优质客户，色选机出海和产品升级带动 25 年收入增长 25Q4 公司收入同比-3%，较前三季度有所放缓，或主要来源于公司经营决 策调整、更为聚焦优质客户。全年公司色选机/医疗设备/工业检测收入分别 同比+8%/-10%/+3.5%。色选机方面，国内农产品色选市场已进入成熟稳 ...

内部控制审计报告 合肥美亚光电技术股份有限公司 容诚审字[2026]230Z0014 号 容诚会计师事务所(特殊普通合伙) 中国·北京 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 内部控制审计报告 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚审字[2026]230Z0014 号 合肥美亚光电技术股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了合肥美亚光电技术股份有限公司（以下简称"美亚光电公司"）2025 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业 ...

审计报告 合肥美亚光电技术股份有限公司 容诚审字[2026] 230Z0013 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 审计报告 | 1-6 | | 2 | 合并资产负债表 | 1 | | 3 | 合并利润表 | 2 | | 4 | 合并现金流量表 | 3 | | 5 | 合并所有者权益变动表 | 4 | | 6 | 母公司资产负债表 | 5 | | 7 | 母公司利润表 | 6 | | 8 | 母公司现金流量表 | 7 | | 9 | 母公司所有者权益变动表 | 8 | | 10 | 财务报表附注 | 9- 107 | 审 计 报 告 容诚审字[2026] 230Z0013 号 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ ...

第二条 董事会是公司经营管理的决策机构，为维护公司和全体股东的利益， 在《公司章程》和股东会的授权范围内，负责公司发展目标和重大经营活动的决 策。 合肥美亚光电技术股份有限公司 董事会议事规则 第一章 总则 第一条 为进一步健全和规范合肥美亚光电技术股份有限公司（以下简称"公 司"）董事会的议事和决策程序，确保董事会的工作效率和科学决策，根据《中 华人民共和国公司法》、《中华人民共和国证券法》、《上市公司治理准则》、 《上市公司独立董事管理办法》等法律法规、行政法规、规范性文件及《公司章 程》的有关规定，并结合公司的实际情况，制定本规则。 第三条 公司董事会由 8 名董事组成（包括 3 名独立董事和 1 名职工代表董 事），设董事长 1 人、可设副董事长 1-2 人，对股东会负责。 第七条 有下列情形之一的，会议召集人应在 10 日内召集临时董事会会议： 1 （一）会议日期和地点； （二）会议期限； （三）事由及议题； （四）发出通知的日期。 （一）董事长认为必要时； （二）代表十分之一以上表决权的股东提议时； （三）三分之一以上董事联名提议时； （四）二分之一以上独立董事联名提议时； 第四条 董事会工作接受 ...